- Emerald and Prima will explore opportunities to co-develop new body and wellness products for the US, Canadian and global markets
- Prima is a privately held Public Benefit Corporation that develops innovative botanicals
- Prima provides active plant-derived therapeutics and broad-spectrum hemp extract with naturally occurring CBD
- Emerald Health Emerald is a cannabis company that markets recreational, medical and wellness-oriented cannabis products
- Emerald Health Therapeutics, Inc. (EMH) opened trading at C$0.215 per share
Emerald Health Therapeutics (EMH) and The Uplifters’ Prima, PBC have signed a letter of intent (LOI).
The partnership will focus on developing new cannabinoid-based wellness products for sale in the United States, Canada, and internationally.
As an initial step in establishing the relationship, Emerald has made a capital investment in Prima’s current financing round of Series Seed-1 preferred stock.
Prima provides active plant-derived therapeutics and broad-spectrum hemp extract with naturally occurring CBD.
Emerald and Prima will explore opportunities to co-develop new science-based body and wellness products for the US, Canadian and global markets and discuss broader corporate partnering options.
“Emerald and Prima share core values with respect to the wellness benefits we both wish to offer consumers through accessible, best-in-class products that are science-backed, results-driven, and values-led,” said Christopher Gavigan, CEO and Founder of Prima.
“With Emerald’s innovation, patents and intellectual property, we see a unique opportunity to collaboratively create distinct new product innovations for the US and global markets.”
“We admire Prima’s premiere consumer packaged goods and branding expertise. Christopher previously co-founded The Honest Company, the iconic mission-driven brand focused on leading the clean lifestyle movement. Alongside him, Prima’s co-founder and COO Laurel Angelica Myers was also deeply embedded in Honest’s product development strategy and execution for over five years as they played a vital role in driving the company to over $300 million in annual revenue. Emerald is pleased to be associated with this calibre of strategic vision, brand excellence and notable accomplishment,” said Riaz Bandali, President and Chief Executive Officer of Emerald.
“With our mutual commitment to innovative product development and medical-grade standards, we look forward to working toward a definitive agreement with Prima, our second initiative with US-based cannabis and cannabinoid marketplace participants.”
Prima is a privately held Public Benefit Corporation that develops innovative botanicals.
Prima’s supplements, topicals, and skincare products are distributed through top-tier retailers including Sephora, Nordstrom, Thrive Market and directly at PRIMA.co.
Emerald Health is a cannabis company that markets recreational, medical and wellness-oriented cannabis products.
Emerald Health Therapeutics, Inc. (EMH) opened trading at C$0.215 per share.